Related Experiment Video

Updated: Aug 22, 2026

Isolation of Primary Human Proximal Tubule Epithelial Cells and Their Use in Creating a Microphysiological Model of the Renal Proximal Tubule
07:06

Isolation of Primary Human Proximal Tubule Epithelial Cells and Their Use in Creating a Microphysiological Model of the Renal Proximal Tubule

Published on: May 9, 2025

Pentoxifylline: a potential therapy for chronic kidney disease

Shuei-Liong Lin1, Yung-Ming Chen, Wen-Chih Chiang

  • 1Department of Internal Medicine, National Taiwan University Hospital and Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

Nephrology (Carlton, Vic.)
|September 15, 2004
PubMed

Insights

Pentoxifylline shows promise in reducing proteinuria for chronic kidney disease patients, particularly those with diabetes or membranous nephropathy. Further research is needed to confirm its long-term renal benefits alongside existing therapies.

Area of Science:

  • Nephrology
  • Pharmacology
  • Fibrosis Research

Background:

  • Chronic kidney disease (CKD) progression to end-stage renal disease is marked by fibrosis.
  • Current interventions like glycemic control, blood pressure management, protein restriction, and angiotensin II blockade slow CKD progression but don't halt it.
  • Multidrug approaches are needed to address CKD's complexity and halt disease progression.

Purpose of the Study:

  • To evaluate the potential of pentoxifylline as an adjunct therapy for chronic kidney disease.
  • To assess pentoxifylline's efficacy in reducing proteinuria and its impact on renal outcomes.

Main Methods:

  • Review of animal and cellular studies on pentoxifylline's anti-fibrotic, anti-inflammatory, and anti-proliferative effects.
  • Analysis of limited human studies investigating pentoxifylline's effect on proteinuria in diabetic nephropathy, nephrotic syndrome, and membranous nephropathy.

Main Results:

  • Animal and cellular studies support pentoxifylline's rationale for treating various CKD types.
  • Human studies indicate pentoxifylline reduces proteinuria in patients on ACE inhibitors and those with refractory nephrotic syndrome.
  • Monotherapy with pentoxifylline significantly reduces proteinuria in membranous nephropathy patients.

Conclusions:

  • Pentoxifylline demonstrates potential in managing proteinuria in specific CKD populations.
  • Further clinical trials are necessary to determine if pentoxifylline improves renal outcomes when combined with established CKD interventions.

More Related Videos

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells06:23

Modeling Hypoxia/Reoxygenation Injury in Proximal Tubular Epithelial Cells

Published on: November 21, 2025

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...